About: RPL-554

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: RPL-554 Goto Sponge NotDistinct Permalink

An Entity of Type : yago:WikicatPhenolEthers, within Data Space : dbpedia.org associated with source document(s)
QRcode icon

http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FRPL-554&graph=http%3A%2F%2Fdbpedia.org&graph=http%3A%2F%2Fdbpedia.org

RPL-554 (LS-193,855) is a drug candidate for respiratory diseases. It is an analog of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3; indeed, it is >3000-times more potent against PDE3 than PDE4. As of October 2015, inhaled RPL-554 delivered via a nebulizer was in development for COPD and had been studied in asthma. PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect.

Attributes	Values
rdf:type	Thing person dul:ChemicalObject chemical substance Drug yago:WikicatMolecularFormulas yago:WikicatUreas yago:Abstraction100002137 yago:Chemical114806838 yago:Communication100033020 yago:Compound114818238 yago:Element114840755 yago:Formula106816935 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 drug yago:Statement106722453 yago:Substance100019613 yago:Urea115085472 yago:WikicatPhenolEthers
rdfs:label	RPL-554 (en)
rdfs:comment	RPL-554 (LS-193,855) is a drug candidate for respiratory diseases. It is an analog of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3; indeed, it is >3000-times more potent against PDE3 than PDE4. As of October 2015, inhaled RPL-554 delivered via a nebulizer was in development for COPD and had been studied in asthma. PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect. (en)
foaf:depiction
dcterms:subject	PDE3 inhibitors PDE4 inhibitors Imines Lactams Phenol ethers Ureas
Wikipage page ID	19258765 (xsd:integer)
Wikipage revision ID	1117834794 (xsd:integer)
Link from a Wikipage to another Wikipage	PDE3 inhibitors PDE4 inhibitors Inhaler Imines Lactams Phenol ethers Ureas GlaxoSmithKline Contract research organization Phosphodiesterase Bronchodilators COPD Trequinsin Allergic rhinitis Asthma Vernalis plc Nebulizer PDE3 inhibitor PDE4 inhibitor
sameAs	RPL-554 RPL-554 RPL-554 RPL-554 RPL-554 RPL-554
dbp:wikiPageUsesTemplate	dbt:Phosphodiesterase_inhibitors dbt:Drugbox dbt:Reflist dbt:Rp dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Stdinchicite
thumbnail	wiki-commons:Special:FilePath/RPL554.png?width=300
c	26 (xsd:integer)
CAS number	298680 (xsd:integer)
CAS supplemental	E-isomer: 1884461-72-6 (en)
ChemSpiderID	8110374 (xsd:integer)
H	31 (xsd:integer)
IUPAC name	N-{2-[-2--9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3-yl]ethyl}urea (en)
n	5 (xsd:integer)
O	4 (xsd:integer)
PubChem	9934746 (xsd:integer)
SMILES	Cc3ccccc3N=c2cc1-ccCCn1cn2CCNC=O (en)
StdInChI	1 (xsd:integer)
StdInChIKey	CSOBIBXVIYAXFM-BYNJWEBRSA-N (en)
synonyms	(9,10-Dimethoxy-2--3--3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one) (en)
UNII	3000 (xsd:integer)
verifiedrevid	461481983 (xsd:integer)
width	240 (xsd:integer)
has abstract	RPL-554 (LS-193,855) is a drug candidate for respiratory diseases. It is an analog of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3; indeed, it is >3000-times more potent against PDE3 than PDE4. As of October 2015, inhaled RPL-554 delivered via a nebulizer was in development for COPD and had been studied in asthma. PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect. RPL554 was part of a family of compounds invented by Sir David Jack, former head of R&D for GlaxoSmithKline, and Alexander Oxford, a medicinal chemist; the patents on their work were assigned to Vernalis plc. In 2005, Rhinopharma Ltd, acquired the rights to the intellectual property from Vernalis. Rhinopharma was a startup founded in Vancouver, Canada in 2004 by Michael Walker, Clive Page, and David Saint, to discover and develop drugs for chronic respiratory diseases, and intended to develop RPL-554, delivered with an inhaler, first for allergic rhinitis, then asthma, then for COPD. RPL554 was synthesized at a contract research organization, under the supervision of Oxford, and was studied in collaboration with Page's lab at King’s College, London. In 2006 Rhinopharma recapitalized and was renamed Verona Pharma plc. (en)
gold:hypernym	Candidate
prov:wasDerivedFrom	wikipedia-en:RPL-554?oldid=1117834794&ns=0
page length (characters) of wiki page	6914 (xsd:nonNegativeInteger)
CAS number	298680-25-8 E-isomer: 1884461-72-6
FDA UNII code	3E3D8T1GIX
PubChem	9934746
foaf:isPrimaryTopicOf	wikipedia-en:RPL-554
is Link from a Wikipage to another Wikipage of	C26H31N5O4 PDE3 inhibitor

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (62 GB total memory, 50 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software